Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia
5.9.2019 16:30:00 EEST | Business Wire | Press release
Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. The MyCare Insite Clozapine Test is the first and only rapid point-of-care test CE marked to aid mental health professionals in the treatment and monitoring of patients with schizophrenia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005085/en/
The MyCare Insite Clozapine Test delivers accurate and precise clozapine blood levels comparable to laboratory results. Psychiatrists need immediate information to make informed decisions during a patient visit. The MyCare Insite Clozapine Test addresses this unmet medical need by providing answers in only six minutes. Clinicians, in consultation with their patients, can use these results to make real-time adjustments to better manage their patients.
"Mental health professionals have very few tools to aid in patient treatment; as a result, patients are suffering. The MyCare Insite Clozapine Test provides clinicians a first of its kind device. The test is evidence of how Saladax is once again setting new standards for innovation in the treatment and monitoring of patients," said Dr. Salvatore Salamone, CEO and Founder of Saladax Biomedical. "We are changing psychiatry with a single drop of blood.”
ABOUT PSYCHOSIS
Psychosis is a condition that affects the way your brain processes information. It causes you to lose touch with reality. Psychotic disorders, like schizophrenia, involve psychosis that usually affects you for the first time in the late teen years or early adulthood. Young people are especially at risk, but doctors don’t know why.
ABOUT THE MyCARE INSITE CLOZAPINE TEST
The MyCare Insite Clozapine Test is intended for the in vitro quantitative measurement of clozapine in human capillary finger blood using the MyCare Insite.
ABOUT SALADAX
Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant at Ben Franklin TechVentures® located on Lehigh University’s campus in Bethlehem, PA.
Saladax develops rapid blood tests for point-of-care and for laboratory analysers for use in psychiatry and oncology. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible causes of treatment failures. These tests enable psychiatrists to more accurately assess adherence and better adjust medication dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2016 certified.
For more information, visit Saladax.com or MyCareTests.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005085/en/
Contact information
Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731
ssalamone@saladax.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Silo Communications expands fiber connectivity in rural Illinois with Adtran16.7.2026 15:00:00 EEST | Press release
Adtran today announced that Silo Communications, a rural broadband provider based in northern Illinois, is using its fiber access portfolio and software applications to expand high-speed connectivity for underserved homes and businesses. As demand for reliable broadband continues to grow across communities, Silo Communications is building on its wireless heritage with a scalable fiber network designed to support higher speeds, stronger service reliability and future expansion. The deployment supports wider state and federal efforts to extend high-speed connectivity to underserved rural areas, strengthening Silo Communications’ ability to connect residents, local enterprises and agricultural businesses that have historically had limited access to high-performance broadband. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716640241/en/ Adtran’s fiber access technology is helping Silo Communications deliver high-speed connect
Elliptic Launches Next-Generation Continuous Monitoring, Giving Crypto Compliance Teams a Live View of Customer Risk Without the Flood of Alerts16.7.2026 15:00:00 EEST | Press release
Elliptic, the global leader in digital asset decisioning, today launched the next generation of Continuous Monitoring, a solution that gives crypto compliance teams a continuously accurate view of customer risk rather than a picture frozen at the last screening. Elliptic's Continuous Monitoring is the most comprehensive risk monitoring solution on the market, and the only one to pair the industry's broadest event detection with fully configurable alerting. It is available to compliance teams today. "Monitoring obligations on MLROs are getting more stringent, putting both their companies and, sometimes, themselves at risk. Existing monitoring solutions fail twice over: They leave exposure gaps by only alerting on obvious triggers like label changes while missing the rest. On the exposure they do catch, they fire so indiscriminately that teams drown in alerts that don’t matter. We’ve built Continuous Monitoring to cover the full range of events that change a customer's risk, and to alert
MultiBank Group Named Forex Broker of the Year 2026 at Money Expo Abu Dhabi16.7.2026 14:35:00 EEST | Press release
MultiBank Group, one of the world's largest and most regulated online financial derivatives institutions, has been named Forex Broker of the Year at Money Expo Abu Dhabi. The event was held on 8–9 July 2026 at the ADNEC Centre. This flagship award recognizes the broker setting the benchmark for excellence across the global trading and fintech industry. MultiBank Group's participation in the expo underscored its leadership position within the Middle East's financial landscape. A Landmark Event for Trading and Fintech Money Expo Abu Dhabi 2026 brought together traders, banks, fintech firms, liquidity providers, and market leaders from across the region and beyond. Winning top honors on this stage sends a clear signal across the entire industry. “Being named Forex Broker of the Year is a defining moment for our Group,” said Johny Giacaman, Chief Business Operations Officer at MultiBank Group. “It reflects two decades of regulatory discipline, technological innovation, and an unwavering co
illumynt Appoints Anthony Giannetti as Senior Vice President of Global Operations16.7.2026 14:00:00 EEST | Press release
illumynt, a technology-driven leader in AI hardware lifecycle recovery and IT asset disposition (ITAD), today announced that Anthony "Tony" Giannetti has joined the company as Senior Vice President of Global Operations, effective July 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716696044/en/ Anthony Giannetti, SVP Global Operations Giannetti brings more than two decades of operations and supply chain leadership from some of the technology industry's largest OEMs, including Dell, where he managed reverse supply chain operations, and Apple and Microsoft, where he held additional operations leadership roles. His background spans production engineering, reverse logistics, and large-scale operational management, disciplines directly relevant to illumynt's work certifying and recovering value from retired AI infrastructure at scale. "Tony has spent his career on the operational side of exactly the problem we solve
Compvide ™ Announces Strategic Collaboration with OpZira ™ to Accelerate Growth and Advance the CIMED ™ Platform16.7.2026 13:47:00 EEST | Press release
Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZira, Inc. to support the company’s continued growth and accelerate development of its proprietary CIMED platform. Through the collaboration, OpZira will provide comprehensive operational support across clinical, customer care, finance, manufacturing, marketing, quality, and regulatory functions,” stated Clark Tedford, Ph.D., President and CEO, OpZira, Inc. “By leveraging OpZira’s established operational infrastructure and expertise, Compvide can remain focused on advancing its scientific innovation while expanding its capabilities in complement-focused diagnostics and translational medicine.” “Partnering with an experienced organization that understands the unique needs of emerging healthcare companies is an important step for Compvide as we continue building the company,” said Sadam Yaseen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom